OBJECTIVE: To assess the effectiveness and safety of a 24-week application of @entity1968 0.025% cream, with an alternate-day regimen, in achieving control of VLS signs and symptoms. METHODS: 17 @entity1 affected with VLS were included. The main efficacy parameters were the response rate, as defined by protocol parameters, the rate of @entity1 achieving an improvement from baseline of >= 75% in the subjective and objective scores, and the mean reduction in subjective and objective scores throughout the treatment. The safety of the treatment was also assessed. RESULTS: By the end of the 24-week treatment, 12 @entity1 (70.6%) experienced a response; 35.3% and 17.6% of @entity1 achieved an improvement of at least 75% in subjective and objective scores, respectively. Mean scores of itching, @entity6506 ( @entity10486 ) and @entity5656 decreased significantly in the study @entity1 , and none presented itching-related excoriations. Erythema increased compared with baseline. Six @entity1 (35.29%) experienced some side effects related to @entity1968 , mainly mild erythema and burning. None of the subjects discontinued the treatment because of side effects. CONCLUSIONS: @entity1968 0.025% cream applied for 24 weeks may represent a useful alternative option to @entity288 in the treatment of active VLS, acting particularly on @entity5656 and @entity10486 .

Topical XXXX in the treatment of vulvar lichen sclerosus: an advisable option?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity10486 :: ('MESH:D010167', 'Disease') :: ['pallor'] @entity5656 :: ('MESH:D017488', 'Disease') :: ['hyperkeratosis'] @entity6506 :: ('MESH:C536955', 'Disease') :: ['leukoderma'] @entity1968 :: ('MESH:D014212', 'Chemical') :: ['Tretinoin', 'tretinoin'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity1968 :: (MESH:D014212,Chemical) :: ['tretinoin']
